Evidence map›Paper›PMID 36181432›Full record

ArticleDiagnostic cytopathology2022

Cervicovaginal cytology, HPV testing and vaginal flora in transmasculine persons receiving testosterone.

Lawrence Hsu Lin, Fang Zhou, Esther Elishaev, Samer Khader, Andrea Hernandez, Alan Marcus, Esther Adler

Open access · greenAbstract read
In one paragraph

Article in Diagnostic cytopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lawrence Hsu LinDepartment of Pathology, NYU Langone Medical Center, New York, New York, USA.ORCID https://orcid.org/0000-0001-9603-9783
Fang ZhouDepartment of Pathology, NYU Langone Medical Center, New York, New York, USA.
Esther ElishaevDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Samer KhaderDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Andrea HernandezDepartment of Pathology, NYU Long Island School of Medicine, Mineola, New York, USA.
Alan MarcusDepartment of Pathology, NYU Langone Medical Center, New York, New York, USA.
Esther AdlerDepartment of Pathology, NYU Langone Medical Center, New York, New York, USA.
NYU Langone Health · USUniversity of Pittsburgh Medical Center · USLong Island University · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
Laura and Isaac Perlmutter Cancer Center Support Grant NIH/NCI P30CA016087NCI NIH HHS P30 CA016087NYULH Center for Biospecimen Research and Development, Histology and Immunohistochemistry Laboratory RRID:SCR_018304
6 · The paper itself

Abstract

backgroundTestosterone is one of the strategies that transmasculine persons can elect in order to align physical traits to their gender identity. Previous studies have shown morphologic changes in the genital tract associated with testosterone. Here, we aim to evaluate cervicovaginal cytology specimens (Pap tests) and high-risk HPV (HR-HPV) testing from transmasculine individuals receiving testosterone.

methodsThis is a retrospective cohort of 61 transmasculine individuals receiving testosterone from 2013 to 2021. Cytologic diagnoses from 65 Pap tests were correlated with HPV status and histologic follow-up and compared with the institutional data and a cohort of cisgender women with atrophic changes.

resultsThe median age was 28 years and median time of testosterone use was 3 years. Transmasculine persons showed significantly higher rates of HSIL (2%) and unsatisfactory (16%) when compared with the institutional data and atrophic cohort of cisgender women. After reviewing slides of 46 cases, additional findings were noted: atrophy was present in 87%, glycogenated cells were seen in 30%, and Lactobacilli were substantially decreased in 89%. Among 32 available HPV tests, 19% were positive for HR-HPV and 81% were negative. On histologic follow-up, all HR-HPV-positive cases with abnormal cytology showed HSIL, while none of the HPV-negative cases revealed HSIL.

conclusionOur study cohort demonstrated a high percentage of abnormal Pap tests in transmasculine persons receiving testosterone. Testosterone seems to induce changes in squamous cells and shifts in vaginal flora. HR-HPV testing can be a useful adjunct in the workup of abnormal Pap tests from transmasculine individuals.

Indexed as

Papillomavirus InfectionsUterine Cervical NeoplasmsAdultFemaleGender IdentityHumansMalePapanicolaou TestPapillomaviridaeRetrospective StudiesTestosteroneVaginal SmearsTestosteronecervical cancerHPVPap testtestosteronetransgender persons

Identifiers

PMID36181432
PMCPMC9529242
OpenAlexW4290652787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.